NWRN.SW - Newron Pharmaceuticals S.p.A.

Swiss - Swiss Delayed Price. Currency in CHF
9.13
-0.15 (-1.62%)
As of 9:20AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close9.28
Open9.30
Bid9.15 x 0
Ask9.22 x 0
Day's Range9.11 - 9.30
52 Week Range8.07 - 16.75
Volume1,885
Avg. Volume41,658
Market Cap162.918M
Beta1.88
PE Ratio (TTM)N/A
EPS (TTM)-0.97
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.84
  • Business Wire12 days ago

    Newron Pharmaceuticals to Host 2018 R&D Day on October 31 in New York City – Save the Date

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that its 2018 R&D Day will be held in New York City on October 31, 2018, from 10:00AM to 1:00PM EDT. Stefan Weber, Chief Executive Officer, Ravi Anand, CMO, and other senior members of Newron’s management team will host the event, which will focus on the Company’s clinical and commercial pipeline, regulatory updates and financial outlook.

  • Business Wire27 days ago

    Newron Pharmaceuticals to Present at H.C. Wainwright Annual Healthcare Conference

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the H.C. Wainwright Annual Healthcare Conference in New York, NY, on Wednesday, September 05, 2018 at 5:30 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire2 months ago

    Newron Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the Wedbush PacGrow Healthcare Conference in New York, NY, on Wednesday, August 15, 2018 at 1:20 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire3 months ago

    Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announces that the STARS clinical study (Sarizotan Treatment of Apneas in Rett Syndrome) in patients with Rett syndrome is expected to complete enrollment in H2 2018. Newron expects to report results from the STARS study in H1 2019. Based on the current rate of screening and qualification, Newron anticipates that randomization of the target number of 129 patients will be completed in H2 2018.

  • Business Wire4 months ago

    Newron Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the Jefferies 2018 Healthcare Conference in New York, NY on Tuesday, June 5, 2018 at 4:30 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire4 months ago

    Newron Pharmaceuticals to Present at the UBS Global Healthcare Conference 2018

    Newron Pharmaceuticals S.p.A. (“Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the UBS Global Healthcare Conference 2018 in New York, NY on Tuesday, May 22, 2018 at 3:30 p.m. ET. Newron (NWRN.SW) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

  • Business Wire6 months ago

    Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that shareholders either unanimously or with vast majorities approved all motions on the agenda of its shareholders’ annual meeting held in Bresso , Italy, today.

  • Business Wire7 months ago

    Newron Announces 2017 Financial Results and Provides Outlook for 2018

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announces its financial results and operational highlights for the year ended December 31, 2017, and provides an outlook for 2018.

  • Business Wire7 months ago

    Newron Supports Global Rare Disease Day® 2018 and Rett Syndrome Studies

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its support of this year’s Rare Disease Day®.

  • Business Wire7 months ago

    Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Bo Jesper Hansen has informed the Board of Directors of his intention to step down as a Non-Executive Director, effective from this year’s Annual Shareholders Assembly taking place on March 27, 2018.

  • Business Wire8 months ago

    Newron Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 20th Annual BIO CEO & Investor Conference in New York, NY on Monday, Feb.

  • Business Wire9 months ago

    Newron Provides End of Year Corporate Update

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today provides an end of year market update.

  • Business Wire10 months ago

    Newron to Participate in Upcoming Investor Conferences in November and December

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and periph

  • Business Wire11 months ago

    Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced recommendations from its advisory board, who are evaluating the burden of disease experienced by patients with Rett syndrome and their families, as well as an update from the recent European Rett Syndrome Congress ...

  • Business Wire11 months ago

    Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced an oral presentation at the upcoming European Rett Syndrome Congress in Berlin, Germany, November 2-4, 2017.

  • Business Wirelast year

    Newron Pharmaceuticals Supports Rett Syndrome Awareness Month this October

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to support Rett Syndrome Awareness Month.